UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

~~August~~September 78, 2025

Date of Report (~~Date~~date of earliest event reported)

___________________________________

Prime Medicine, Inc.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware(State or other jurisdiction of incorporation)	001-41536(Commission File Number)	84-3097762(I.R.S. Employer Identification No.)
60 First StreetCambridge, MA		02141
60 First StreetCambridge, MA 02141
(Address of principal executive offices)		(Zip Code)
(Address of principal executive offices and zip code)
(617) 465-0013
(Registrant's telephone number, including area code)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol~~(s)~~

Name of each exchange on which registered

Common stock, par value $.00001 per share

PRME

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or ~~Rule12b~~Rule 12b-2 of the Securities Exchange Act of 1934 (§250.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 27.0201 ~~Results~~Regulation ofFD ~~Operations and Financial Condition~~Disclosure.

On ~~August~~September 78, 2025, Prime Medicine, Inc. (the “"Company”") ~~issued~~posted aan ~~press~~updated ~~release~~corporate ~~announcing~~presentation to its ~~financial~~website ~~results~~at ~~and business highlights for the quarter ended June 30, 2025~~https://investors.primemedicine.com/news-events. A copy of the ~~press~~corporate ~~release~~presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference. Reference to the Company’s website is for inactive textual reference only and the content of the website should not be deemed incorporated by reference into this Current Report on Form 8-K.

The information ~~contained~~ in ~~Item 2.02 of~~ this ~~Current~~Item ~~Report on Form 8-K~~7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 - Financial Statements and Exhibits.

(d) Exhibits

ExhibitNumber						Description
99.1						~~Press~~Corporate ~~Release~~Presentation, dated ~~August~~September 7, 2025~~, furnished herewith.~~
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: ~~August~~September 78, 2025

Prime Medicine, Inc. By: /s/ Allan Reine Name: Allan Reine, M.D. Title: Chief Executive Officer

Filing Compare · Prime Medicine, Inc.